Development of small molecule SUMO1 inhibitors for treatment of glioblastoma
Ended Cooperative Agreement Awarded Last action
- Award ID
- R43CA224461
- Recipient
-
HB Therapeutics Inc. UEI ELJFQZFNLS48
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Indianapolis, IN 46202, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $300,000 |
Quick answers
Who received award R43CA224461?
R43CA224461 was awarded to HB Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on July 6, 2018.
How much is award R43CA224461 worth?
$300,000 has been obligated on R43CA224461.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award